8-K: Organogenesis Reports Record 2025 Revenue, Navigates 2026 CMS Changes

Organogenesis Holdings Inc. announced record net product revenue for fiscal year 2025, reaching $563.0 million, despite anticipating a challenging first half of 2026 due to CMS payment reforms.

Summary

• Net product revenue for the fourth quarter of 2025 was $225.1 million, an increase of 78% compared to $126.7 million in Q4 2024.
• Advanced Wound Care product revenue increased by 83% to $217.2 million in Q4 2025.
• Surgical & Sports Medicine product revenue decreased by 2% to $7.9 million in Q4 2025.
• Net income for the fourth quarter of 2025 was $43.7 million, up from $7.7 million in Q4 2024.
• Adjusted EBITDA for the fourth quarter of 2025 was $84.2 million, a 363% increase from $18.2 million in Q4 2024.
• Net product revenue for the full fiscal year 2025 was $563.0 million, an increase of 17% compared to $482.0 million in FY 2024.
• Advanced Wound Care product revenue increased by 17% to $531.2 million for FY 2025.
• Surgical & Sports Medicine product revenue increased by 12% to $31.8 million for FY 2025.
• Net income for the full fiscal year 2025 was $37.0 million, up from $0.9 million in FY 2024.
• Adjusted EBITDA for the full fiscal year 2025 was $98.1 million, a 97% increase from $49.8 million in FY 2024.
• Cash, cash equivalents and restricted cash totaled $94.3 million as of December 31, 2025, down from $136.2 million as of December 31, 2024.
• The company had no outstanding debt obligations as of December 31, 2025.
• For fiscal year 2026, the company expects total net revenue between $350.0 million and $420.0 million, representing a decline of 25% to 38% from FY 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report; while 2025 performance was strong with record revenues and improved profitability, the significant projected revenue decline for 2026 due to CMS changes introduces considerable near-term uncertainty.

Positives

• Achieved record net product revenue of $563.0 million for fiscal year 2025, an increase of 17% year-over-year.
• Reported a substantial 78% increase in net product revenue for Q4 2025, reaching $225.1 million.
• Advanced Wound Care products demonstrated strong growth, with an 83% increase in Q4 2025 revenue and a 17% increase for FY 2025.
• Net income significantly improved, rising to $43.7 million in Q4 2025 (from $7.7 million in Q4 2024) and to $37.0 million for FY 2025 (from $0.9 million in FY 2024).
• Adjusted EBITDA saw robust growth, increasing by 363% to $84.2 million in Q4 2025 and by 97% to $98.1 million for FY 2025.
• Operating income for FY 2025 turned positive at $44.7 million, compared to an operating loss of ($1.3) million in FY 2024.
• The company maintains a strong balance sheet with no outstanding debt obligations as of December 31, 2025.

Negatives

• Surgical & Sports Medicine product revenue experienced a slight decrease of 2% in Q4 2025, totaling $7.9 million.
• Cash, cash equivalents and restricted cash declined to $94.3 million as of December 31, 2025, from $136.2 million at the end of 2024.
• The company projects a significant decline in total net revenue for fiscal year 2026, expecting between $350.0 million and $420.0 million, which is a 25% to 38% decrease from 2025.
• A substantial year-over-year decline in revenue is specifically anticipated for the first quarter of 2026 due to market adaptation to CMS changes.

Risks

• The impact of any changes to the coverage and reimbursement levels for the company's products, particularly in light of CMS updated 2026 Medicare reimbursement and coverage changes.
• Significant and continuing competition in the markets the company operates in.
• Rapid technological change could cause the company's products to become obsolete if product offerings are not enhanced through research and development efforts.
• The necessity to convince physicians that the company's products are safe and effective alternatives to existing treatments.
• The company's ability to raise funds to expand its business.
• The potential for future losses, given that the company has incurred losses in prior periods.
• Changes in applicable laws or regulations.
• Adverse effects from other economic, business, and/or competitive factors.
• The company's ability to maintain production or obtain supply of its products in sufficient quantities to meet demand.
• The company's ability to build out its Smithfield, Rhode Island facility on time and on budget.
• The ability to obtain regulatory approval for and successfully commercialize ReNu.

Future Outlook

The company expects total net revenue for fiscal year 2026 to be between $350.0 million and $420.0 million, representing a decline of 25% to 38% from 2025. This guidance assumes a significant year-over-year decline in revenue for the first quarter of 2026, followed by strong quarter-over-quarter growth in the subsequent quarters of 2026. Management anticipates a period of market transition in 2026 due to CMS payment reforms for skin substitutes, with a return to normalized growth expected in 2027 and significant market share gains in the second half of 2026.

Management Comments

• "We delivered record performance in 2025 by demonstrating a sustained ability to execute on our strategy in a complex and challenging market." Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis.
• "With meaningful payment reform in place, we believe we are well positioned to navigate short-term market confusion and deliver long-term growth driven by the most comprehensive and evidenced-backed portfolio on the market." Gary S. Gillheeney, Sr.
• "While we expect the first half of 2026 to be impacted by the market adapting to the sweeping changes from CMS to reform coverage and payment for skin substitutes, we expect to drive significant market share gains in the second half of 2026, and we remain confident in the long-term opportunity for Organogenesis." Gary S. Gillheeney, Sr.
• "After a period of transition in the market in 2026, we expect to return to normalized growth in 2027." Gary S. Gillheeney, Sr.

Industry Context

StockSavvy.ai notes that the regenerative medicine and advanced wound care markets are subject to significant regulatory and reimbursement changes, as evidenced by the CMS updates to coverage and payment for skin substitutes impacting Organogenesis's 2026 outlook. The company's strategy to navigate this "complex and challenging market" and aim for market share gains in the latter half of 2026 suggests a proactive approach to adapting to evolving healthcare policies, a common challenge for companies in this sector.

Stakeholder Impact

• Shareholders: Positive 2025 financial performance but significant revenue decline projected for 2026 could impact short-term stock performance. Long-term growth confidence is expressed.
• Customers (Healthcare Providers): Adapting to new CMS coverage and payment reforms for skin substitutes, which may influence product adoption and purchasing decisions.
• Employees: Restructuring charges were mentioned in 2024 (footnote 2 for Adjusted EBITDA), indicating past impact, but no new specific employee impacts are detailed for 2025/2026.
• Suppliers: The company's ability to maintain production and obtain supply of its products in sufficient quantities to meet demand is a risk factor.

Next Steps

• Management will host a conference call on February 26, 2026, at 5:00 p.m. Eastern Time to discuss results and provide a corporate update.
• The company expects to drive significant market share gains in the second half of 2026.
• The company expects to return to normalized growth in 2027.
• Building out the Smithfield, Rhode Island facility on time and on budget.
• Obtaining regulatory approval for and successfully commercializing ReNu.

Key Dates

Recommendation

While Organogenesis delivered strong financial results in 2025 with record revenue and improved profitability, the significant projected revenue decline for 2026, driven by CMS payment reforms, introduces substantial near-term uncertainty. The market transition period in 2026 and the expectation of normalized growth only in 2027 suggest a cautious approach. Investors should hold to monitor the company's ability to navigate these regulatory changes, achieve projected market share gains in H2 2026, and return to growth in 2027 before making further investment decisions.

Keywords

regenerative medicine, advanced wound care, surgical sports medicine, biotechnology, medical devices, SEC filing, financial results, earnings, ORGO, CMS reimbursement, wound healing, tissue innovation